This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The study includedrandomised controlled trials dealing with adults whoseduodenal ulcer (DU) fulfilled two criteria: (1) it was larger than 5mm diameter and (2) its healing was identified by endoscopy at set intervals (e.g. four weeks, eight weeks).
Sources searched to identify primary studies
MEDLINE and other sources were used to identify the primary studies although specific details of the "other sources" were not given.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The study included 26 ranitidine trials and 24 omeprazole trials. A recent meta-analysis was the main source of the H pylori eradication probabilities. The total number of primary studies included in the review was not explicitly specified and could not be derived from the references given in the paper.
Methods of combining primary studies
The only method mentioned for the combination of primary studies was pooling of data from the trials for each regimen to estimate the required clinical probabilities.
Investigation of differences between primary studies
Results of the review
The ulcer healing probabilities for ranitidine at four weeks and eight weeks were 72% and 86%, respectively. The corresponding values for omeprazole were 64% at two weeks and 87% at four weeks. The ulcer recurrence probability at six months in the placebo group was 56%. The corresponding value for patients given continuous maintenance ranitidine was 12%, and 53% for patients with H pylori. An adjustment rate of 0.75 was used to estimate the endoscopically detected recurrence rates. The eradication rates and 95% confidence intervals for C1 to C6 were reported(with the exception of C2 which was not reported).
The eradication rate (and confidence intervals) were: C1: 61% (57-66) C3: 84% (79-90) C4: 85% (75-96) C5: 91% (88-94) C6: 86% (80-92). 
Methods used to derive estimates of effectiveness

Estimates of effectiveness and key assumptions
Ulcer-free time per healing episode was 2.15 weeks for a 4-weeks episode of omeprazole therapy, and four to six ulcerfree weeks for an 8-week episode of treatment with ranitidine. The total expected ulcer weeks per patient over the 12-month period for all strategies were: A1 (5.7), A2 (3.1), B1 (4.0), C1 (2.4), C2 (2.3), C3 (2.1), C4 (2.1), C5 (2.0) and C6 (3.8).
Measure of benefits used in the economic analysis
The measure of benefits was the total expected ulcer time per patient over the 12-month period.
Direct costs
Drug regimens were reported separately for each strategy. The resources used for the treatment of patients with symptoms of ulcer recurrence were not reported separately. The expected costs per patient were estimated for each health technology. Unit price was calculated and reported for all the drug regimens used in the study. Physician and hospital service costs were calculated but not reported in the paper. The costs were calculated from a governmental third-party payer's perspective. The sources of cost data consisted of a district database, a small survey of local pharmacies, an expert physician panel in association with a modified Delphi technique, and two district health organisations. The costs were adjusted to 1995 prices. The cost of endoscopy was omitted from the study since it was common across all health technologies. The costs of side effects were not considered in the study.
Indirect Costs
Not reported.
Currency
Canadian dollars (Can$).
Sensitivity analysis
A set of one-way sensitivity analyses was performed, although the parameters on which the analyses were carried out were not explicitly stated. The estimated 95% confidence intervals of eradication rates were used to perform a set of one-way sensitivity analysis.
Estimated benefits used in the economic analysis
The total expected ulcer weeks per patient over the 12-month period for all strategies were: A1 (5.7), A2 (3.1), B1 (4.0), C1 (2.4), C2 (2.3), C3 (2.1), C4 (2.1), C5 (2.0) and C6 (3.8). The side-effects of the treatment approaches were not considered in the economic analysis.
Cost results
The expected costs per patient (CAN$) over the 12-month period for all strategies were: A1 (Can$306), A2 (Can$343), B1 (Can$353), C1 (Can$387), C2 (Can$482), C3 (Can$292), C4 (Can$337), C5 (Can$306), and C6 (Can$226). The costs of side effects were not considered in the study.
Synthesis of costs and benefits
A comprehensive synthesis of cost and benefits for all strategies was not carried out since the intermittent strategies (A1 and A2) and the continuous maintenance strategy (B1) were dominated by H pylori eradication strategies C3 and C5. Incremental cost-effectiveness ratios (relative to strategy C6) were calculated to select the cost-effective strategies
